Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol vs Calcifediol for Post-Transplant Hyperparathyroidism
NCT01939977Phase 4Completed
- Sponsor
- Fundación Senefro
- Start
- Jan 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of paricalcitol oral solution in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Fundación Senefro. Primary endpoint: Percentage of Patients With iPTH Serum Concentration >110 pg/mL at 6 months. Started Jan 2014; status: completed.
02
Drugs
paricalcitol oral solution
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01939977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939977.